Get the Stockscreener App
18.56
2.32%
0.42
After Hours:
18.56
Assembly Biosciences Inc stock is traded at $18.56, with a volume of 27,419.
It is up +2.32% in the last 24 hours and up +14.29% over the past month.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
See More
Previous Close:
$18.14
Open:
$18
24h Volume:
27,419
Relative Volume:
1.10
Market Cap:
$131.75M
Revenue:
-
Net Income/Loss:
$-61.23M
P/E Ratio:
-1.3728
EPS:
-13.5194
Net Cash Flow:
$22.49M
1W Performance:
+2.43%
1M Performance:
+14.29%
6M Performance:
+6.85%
1Y Performance:
+40.50%
1-Day Range:
$18.00
$18.99
1-Week Range:
$17.45
$18.99
52-Week Range:
$7.75
$19.93
Assembly Biosciences Inc Stock (ASMB) Company Profile
Name
Assembly Biosciences Inc
Sector
Industry
Phone
(833) 409-4583
Address
TWO TOWER PLACE, SOUTH SAN FRANCISCO
Compare ASMB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ASMB
Assembly Biosciences Inc
|
18.56 | 131.75M | 0 | -61.23M | 22.49M | -13.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.41 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
538.11 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.13 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
546.04 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
240.99 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Assembly Biosciences Inc Stock (ASMB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-25-25 | Initiated | Guggenheim | Buy |
| Sep-20-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-13-21 | Initiated | H.C. Wainwright | Neutral |
| Sep-02-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Mar-23-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Nov-06-20 | Downgrade | Jefferies | Buy → Hold |
| Oct-19-20 | Initiated | Truist | Buy |
| Oct-16-19 | Initiated | Mizuho | Buy |
| Nov-19-18 | Initiated | Leerink Partners | Outperform |
| Oct-08-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| Aug-08-18 | Initiated | Robert W. Baird | Outperform |
| Apr-13-18 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jan-05-18 | Initiated | B. Riley FBR, Inc. | Neutral |
| Nov-08-17 | Initiated | Jefferies | Buy |
| May-30-17 | Initiated | Chardan Capital Markets | Buy |
View All
Assembly Biosciences Inc Stock (ASMB) Latest News
Where are the Opportunities in (ASMB) - news.stocktradersdaily.com
Assembly Biosciences, Inc. (NASDAQ:ASMB) Short Interest Down 47.1% in May - Defense World
Live Biotherapeutic Products and Microbiome CDMO Market Size to Hit USD 1,496.69 Mn by 2034 - Precedence Research
Assembly Biosciences (NASDAQ:ASMB) Stock Crosses Above Two Hundred Day Moving Average – Here’s Why - Defense World
Assembly Biosciences expands stock plans, appoints new CFO By Investing.com - Investing.com Nigeria
Assembly Biosciences expands stock plans, appoints new CFO - Investing.com
Assembly Biosciences Announces Stock Plan Amendments and Leadership Change - TipRanks
Assembly Biosciences IncJeanette M. Bjorkquist Appointed Principal Financial Officer On June 5- SEC Filing - MarketScreener
(ASMB) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Assembly Biosciences, Inc. (NASDAQ:ASMB) Shares Sold by Northern Trust Corp - Defense World
When Will Assembly Biosciences, Inc. (NASDAQ:ASMB) Breakeven? - Yahoo Finance
Assembly Biosciences, Inc. (NASDAQ:ASMB) Short Interest Up 99.2% in May - Defense World
Assembly Biosciences to Present During the Jefferies 2025 Global Healthcare Conference | ASMB Stock News - GuruFocus
Assembly Biosciences to Present During the Jefferies 2025 Global Healthcare Conference - The Manila Times
Assembly Bio Leadership Team Set for Key Presentation at Major Jefferies Healthcare Conference - Stock Titan
Syndeio Biosciences Launches to Lead the Emerging Field of Synapse-Targeted Neurotherapeutics - Business Wire
Assembly’s NeosAI, Powered by Microsoft Azure AI Foundry, Sets New Benchmark for Legal Productivity—Backed by Real-World Results - GlobeNewswire Inc.
Mizuho Cuts Price Target on Assembly Biosciences to $29 From $36, Keeps Outperform Rating - marketscreener.com
ABI-4334 outperforms vebicorvir in HBV suppression - BioWorld MedTech
Assembly Biosciences (ASMB) Reports Q1 Loss, Tops Revenue Estimates - MSN
Growth Investors: Industry Analysts Just Upgraded Their Assembly Biosciences, Inc. (NASDAQ:ASMB) Revenue Forecasts By 33% - simplywall.st
Assembly Biosciences First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Zacks Research Cuts Earnings Estimates for Las Vegas Sands - Defense World
Assembly Biosciences: Q1 Earnings Snapshot - New Haven Register
Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates - The Manila Times
Assembly Biosciences Reports Q1 2025 Earnings - TipRanks
Assembly Biosciences Inc (ASMB) Q1 2025 Earnings: EPS of -$1.17 Beats Estimate, Revenue of $9.4M Exceeds Forecast - GuruFocus
Assembly Biosciences Updates on Clinical Progress and Financials, Anticipates Key Data in 2025 - Nasdaq
Assembly Biosciences (ASMB) Highlights Promising Preclinical Data at EASL Congress | ASMB Stock News - GuruFocus
New Preclinical Data for Assembly Biosciences' Oral Hepatitis D Virus Entry Inhibitor ABI-6250 and Next-Generation Hepatitis B Virus Capsid Assembly Modulator ABI-4334 Presented at the EASL Congress 2025 - The Manila Times
Ribbon Bio Launches MiroSynth™ DNA Molecules to Unlock a New Era of Complex Synthetic DNA - Yahoo Finance
Raymond James Financial Inc. Invests $973,000 in Invesco 0-5 Yr US TIPS ETF (BATS:PBTP) - The AM Reporter
Assembly Biosciences (ASMB) Soars 24.0%: Is Further Upside Left in the Stock? - NewsBreak: Local News & Alerts
Learn to Evaluate (ASMB) using the Charts - news.stocktradersdaily.com
JPMorgan Chase & Co. Acquires 7,918 Shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) - Defense World
Assembly Biosciences Insiders Added US$679.4k Of Stock To Their Holdings - simplywall.st
Assembly Biosciences (NASDAQ:ASMB) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Renaissance Technologies LLC Boosts Stock Holdings in Assembly Biosciences, Inc. (NASDAQ:ASMB) - Defense World
BridgeBio Pharma (BBIO) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Long Term Trading Analysis for (ASMB) - news.stocktradersdaily.com
Assembly Biosciences director sells $7,455 in stock - Investing.com Australia
Assembly Biosciences director sells $7,455 in stock By Investing.com - Investing.com South Africa
Takeda's ENTYVIO Continues Growth Trajectory in Ulcerative Colitis and Crohn's Disease | DelveInsight - PR Newswire UK
Assembly Biosciences Presents New Data Highlighting Long-Acting - GuruFocus
Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress - The Manila Times
Down -22.6% in 4 Weeks, Here's Why Assembly Biosciences (ASMB) Looks Ripe for a Turnaround - Yahoo Finance
ASMB stock touches 52-week low at $8.21 amid market challenges - Investing.com
Assembly Biosciences Inc Stock (ASMB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Assembly Biosciences Inc Stock (ASMB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bjorkquist Jeanette M | Principal Accounting Officer |
Mar 31 '25 |
Sale |
9.85 |
180 |
1,773 |
4,617 |
| Okazaki Jason A | CEO and President |
Mar 31 '25 |
Sale |
9.85 |
355 |
3,496 |
14,757 |
| White Nicole S | Chief Manufacturing Officer |
Mar 31 '25 |
Sale |
9.85 |
197 |
1,940 |
11,674 |
| Houghton Michael | Director |
Dec 30 '24 |
Buy |
15.61 |
3,202 |
49,998 |
3,202 |
| GILEAD SCIENCES, INC. | 10% Owner |
Dec 19 '24 |
Buy |
21.37 |
940,499 |
20,098,464 |
2,209,471 |
| Schornstein Alexander | 10% Owner |
Nov 22 '24 |
Buy |
14.87 |
17,024 |
253,104 |
720,137 |
| Schornstein Alexander | 10% Owner |
Nov 25 '24 |
Buy |
14.91 |
7,976 |
118,890 |
728,113 |
| White Nicole S | Chief Manufacturing Officer |
Nov 18 '24 |
Sale |
16.29 |
40 |
652 |
11,871 |
| Schornstein Alexander | 10% Owner |
Oct 08 '24 |
Buy |
14.58 |
10,000 |
145,800 |
703,113 |
| White Nicole S | Chief Manufacturing Officer |
Oct 03 '24 |
Sale |
14.81 |
157 |
2,325 |
11,911 |
1.08%
2.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):